Benitec Biopharma (BNTC) News
NASDAQ: BNTCHealth CareBiotechnology: Pharmaceutical PreparationsUSD
7.92-0.225 (-2.76%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BNTC news summary
We found 4 recent headlines mentioning Benitec Biopharma (BNTC): 0 in the past week and 4 in the past 30 days, most often from GlobeNewswire, Nasdaq. For price context, BNTC is down 2.76% at $7.92. The most recent story, "UPDATED -- Benitec Biopharma Releases First Quarter 2027 Fiscal-Year Financial Results and Provides Operational Update", was published by GlobeNewswire on Nov 13, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Benitec Biopharma headlines
- UPDATED -- Benitec Biopharma Releases First Quarter 2027 Fiscal-Year Financial Results and Provides Operational UpdateBenitec Biopharma Releases First Quarter 2027 Fiscal-Year Financial Results and Provides Operational UpdateGlobeNewswire
- Benitec Biopharma Releases First Quarter 2027 Fiscal-Year Financial Results and Provides Operational UpdateBenitec Biopharma Releases First Quarter 2027 Fiscal-Year Financial Results and Provides Operational UpdateGlobeNewswire
- Weekly Buzz: ABBV, PFE Win FDA Nod; ARTV Slashes Jobs; DAVI, SGRY Strike Deals(RTTNews) - The biotech sector stayed active this week, with a mix of regulatory approvals, strategic partnerships, M&A activity, and clinical trial developments.NasdaqAARD, ABBV, ARTV, AZN
- Benitec Biopharma Inc. Announces Positive Interim Phase 1b/2a Results for High Dose BB-301Benitec Biopharma Inc. announced positive interim clinical results from its ongoing BB-301 Phase 1b/2a first-in-human study (NCT06185673) for patients treated with high dose BB-301 and continued…Nasdaq